FRM
JANX icon

Fox Run Management’s Janux Therapeutics JANX Stock Holding History

Fox Run Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211K Sell
13,729
-3,648
-21% -$52.8K 0.04% 797
2026
Q1 		$226K Sell
17,377
-795
-4% -$10.9K 0.04% 719
2025
Q4 		$251K Sell
18,172
-6,122
-25% -$144K 0.04% 748
2025
Q3 		$594K Buy
+24,294
New +$592K 0.09% 421

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Fox Run Management's JANX Position: Q2 2026 in Review

Fox Run Management reduced its Janux Therapeutics (JANX) stake by 21% in Q2 2026, selling an estimated $52.8K and leaving 13,729 shares worth $211K. The position accounts for 0.04% of the portfolio, ranked #797.

Fox Run Management first reported a position in JANX in Q3 2025 and has held it in 4 quarters since. The position peaked at $594K in Q3 2025. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Fox Run Management held 13,729 shares of Janux Therapeutics worth $211K as of Q2 2026.
  • Fox Run Management sold 3,648 Janux Therapeutics shares in Q2 2026, an estimated $52.8K.
  • Janux Therapeutics made up 0.04% of Fox Run Management's portfolio in Q2 2026, its #797 holding.
  • Fox Run Management first reported a position in Janux Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Fox Run Management's Janux Therapeutics position peaked at $594K in Q3 2025.
  • 198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.